<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Follow-up management of COPD*</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Follow-up management of COPD*</h1>
<div class="graphic"><div class="figure"><div class="ttl">Follow-up management of COPD*</div><div class="cntnt"><table cellspacing="0"><colgroup width="35%"></colgroup><colgroup width="65%"></colgroup> <tbody> <tr> <td class="subtitle1_left" colspan="2">No exacerbations and no dyspnea/low COPD impact (ie, mMRC 0 to 1 or CAT &lt;10)<sup>¶</sup></td> </tr> <tr> <td class="subtitle2_left">Current therapy</td> <td class="subtitle2_left">Actions</td> </tr> <tr> <td class="indent1">SABA or SABA-SAMA as needed</td> <td class="indent1">Continue current therapy</td> </tr> <tr> <td class="indent1">LAMA, LABA, or LAMA-LABA</td> <td class="indent1">Continue current therapy</td> </tr> <tr> <td class="indent1">LABA-ICS or LABA-LAMA-ICS</td> <td class="indent1">Taper or discontinue ICS dose to reduce adverse effects of ICS<sup>Δ</sup></td> </tr> <tr> <td class="subtitle1_left" colspan="2">Persistent dyspnea or high COPD impact (ie, mMRC ≥2 or CAT ≥10)<sup>¶</sup> with no exacerbations</td> </tr> <tr> <td class="subtitle2_left">Current therapy</td> <td class="subtitle2_left">Actions</td> </tr> <tr> <td class="indent1">SABA or SABA-SAMA as needed</td> <td class="indent1">Add LAMA or LABA</td> </tr> <tr> <td class="indent1">LAMA or LABA monotherapy</td> <td class="indent1">Change to LAMA-LABA</td> </tr> <tr> <td class="indent1">LABA-ICS</td> <td class="indent1"> <ul> <li>LAMA-LABA-ICS</li> <li>LAMA-LABA if lack of response to ICS or adverse effects from ICS</li> </ul> </td> </tr> <tr> <td class="indent1">LAMA-LABA</td> <td class="indent1"> <ul> <li>Substitute alternate delivery system or different LAMA-LABA agents</li> <li>Trial of LAMA-LABA-ICS, in patients with blood eosinophils ≥100 cells/microL<sup>◊</sup></li> <li>Additional interventions may include low-dose theophylline, repeat pulmonary rehabilitation, and nonpharmacologic therapies<sup>§</sup></li> </ul> </td> </tr> <tr> <td class="indent1">LAMA-LABA-ICS</td> <td class="indent1"> <ul> <li>Continue LAMA-LABA-ICS</li> <li>Additional interventions may include low-dose theophylline, repeat pulmonary rehabilitation, and nonpharmacologic therapies for COPD<sup>§</sup></li> <li>Stop ICS, if initial indication unclear, lack of response, or adverse effect to ICS<sup>Δ</sup></li> </ul> </td> </tr> <tr> <td class="subtitle1_left" colspan="2">1 or more exacerbations in past year <span class="nowrap_whitespace">+/–</span> persistent dyspnea or high COPD impact (ie, mMRC ≥2 or CAT ≥10)<sup>¶</sup></td> </tr> <tr> <td class="subtitle2_left">Current therapy<sup>§</sup></td> <td class="subtitle2_left">Actions</td> </tr> <tr> <td class="indent1">SABA or SABA-SAMA as needed</td> <td class="indent1">Add LAMA</td> </tr> <tr> <td class="indent1">LAMA or LABA monotherapy</td> <td class="indent1"> <ul> <li>LAMA-LABA, if blood eosinophil count &lt;300/microL<sup>◊</sup> <p class="indent1 extra_spacing"><strong>or</strong></p> </li> <li>LAMA-LABA-ICS, if blood eosinophil count ≥300/microL<sup>◊</sup> <strong>or</strong> hospitalization for COPD exacerbation <p class="indent1 extra_spacing"><strong>or</strong></p> </li> <li>LABA-ICS, if blood eosinophil count ≥100/microL<sup>◊</sup> <strong>and</strong> LAMA contraindicated</li> </ul> </td> </tr> <tr> <td class="indent1">LAMA-LABA</td> <td class="indent1"> <ul> <li>LAMA-LABA-ICS, if blood eosinophil count ≥100/microL<sup>◊</sup> <p class="indent1 extra_spacing"><strong>or</strong></p> </li> <li>Continue LAMA-LABA, if blood eosinophil count &lt;100/microL<sup>¥</sup> <ul class="none"> <li>Add roflumilast<sup>‡</sup> <p class="indent1 extra_spacing"><strong>or</strong></p> </li> <li>Add azithromycin<sup>†</sup></li> </ul> </li> </ul> </td> </tr> <tr> <td class="indent1">LABA-ICS</td> <td class="indent1"> <ul> <li>LAMA-LABA-ICS <p class="indent1 extra_spacing"><strong>or</strong></p> </li> <li>LAMA-LABA if lack of response to ICS or adverse effects from ICS<sup>Δ</sup></li> </ul> </td> </tr> <tr> <td class="indent1">LAMA-LABA-ICS</td> <td class="indent1"> <ul> <li>Continue LAMA-LABA-ICS <ul class="none"> <li>Add roflumilast<sup>‡</sup> <p class="indent1 extra_spacing"><strong>or</strong></p> </li> <li>Add azithromycin<sup>†</sup></li> </ul> </li> <li>Stop ICS if initial indication unclear, lack of response, or adverse effects of ICS<sup>Δ</sup></li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>COPD: chronic obstructive pulmonary disease; mMRC: modified Medical Research Council; CAT: COPD Assessment Test; SABA: short-acting beta-agonist; SAMA: short-acting muscarinic-antagonist; LAMA: long-acting muscarinic-antagonist; LABA: long-acting beta-agonist; ICS: inhaled corticosteroids (glucocorticoids); BMI: body mass index; SpO<sub>2</sub>: pulse oxygen saturation; FEV<sub>1</sub>: forced expiratory volume in one second.</p>
<p>* Adjustments to pharmacologic therapy for COPD are based on an assessment of dyspnea/exercise limitation (mMRC or CAT), frequency of exacerbations, and peripheral blood eosinophil counts. Follow-up visits are also an opportunity to assess and reinforce nonpharmacologic interventions for COPD, including: smoking cessation; inhaler technique and adherence to medications; administration of pneumococcal and seasonal influenza vaccinations; pulmonary rehabilitation; and nutrition counselling regarding healthy diet and normal BMI. All patients with COPD should have a rapid relief inhaler available, either a SABA or a SABA-SAMA (SABA preferred for patients using a LAMA). Refer to UpToDate content on the overview of management for stable COPD.</p>
<p>¶ mMRC dyspnea scale: <a href="https://www.pcrs-uk.org/mrc-dyspnoea-scale" target="_blank">https://www.pcrs-uk.org/mrc-dyspnoea-scale</a>; CAT evaluates health impact of COPD: <a href="https://www.catestonline.org" target="_blank">https://www.catestonline.org</a>.</p>
<p>Δ If blood eosinophil count ≥300 cells/microL, patient is more likely to experience exacerbations after ICS withdrawal. Close patient monitoring is required if ICS are withdrawn.</p>
<p>◊ In patients with exacerbations and blood eosinophil count ≥300 cells/microL, the addition of ICS is likely to be of benefit. For patients with eosinophil counts ≥100 but &lt;300 cells/microL, ICS may improve exacerbation rates and pulmonary function.</p>
<p>§ Nonpharmacologic measures (eg, oxygen therapy if SpO<sub>2</sub> ≤88%, pulmonary rehabilitation, bronchoscopic or surgical lung volume reduction, lung transplantation) can help reduce dyspnea and exacerbations. Contributing comorbidities should be evaluated and treated. Not all patients achieve control of dyspnea or exacerbations despite optimal available pharmacotherapy.</p>
<p>¥ For patients with a blood eosinophil count &lt;100 cells/microL, there is a low likelihood that addition of ICS will be beneficial and higher risk of pneumonia after the addition of ICS.</p>
<p>‡ Roflumilast is used for patients with chronic bronchitis and FEV<sub>1</sub> &lt;50% predicted, particularly if there has been at least 1 hospitalization for an exacerbation in the past year. Potential adverse effects may limit use.</p>
† Azithromycin preventive therapy is more effective in patients who are not current smokers. However, it may lead to development of resistant organisms.</div><div class="graphic_reference">Adapted from: Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (2023 Report). Available at: <a href="http://www.goldcopd.org" target="_blank">www.goldcopd.org</a> (Accessed on December 13, 2022).</div><div id="graphicVersion">Graphic 122795 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
